COVID-19 恢复期血浆疗法降低炎症细胞因子：一项随机对照试验。
COVID-19 convalescent plasma therapy decreases inflammatory cytokines: a randomized controlled trial.
机构信息
Department of Medicine, Division of Infectious Diseases, Johns Hopkins School of Medicine, Johns Hopkins University , Baltimore, Maryland, USA.
Department of Pathology, Johns Hopkins School of Medicine, Johns Hopkins University , Baltimore, Maryland, USA.
出版信息
Microbiol Spectr. 2024 Jan 11;12(1):e0328623. doi: 10.1128/spectrum.03286-23. Epub 2023 Nov 27.
This study examined the role that cytokines may have played in the beneficial outcomes found when outpatient individuals infected with SARS-CoV-2 were transfused with COVID-19 convalescent plasma (CCP) early in their infection. We found that the pro-inflammatory cytokine IL-6 decreased significantly faster in patients treated early with CCP. Participants with COVID-19 treated with CCP later in the infection did not have the same effect. This decrease in IL-6 levels after early CCP treatment suggests a possible role of inflammation in COVID-19 progression. The evidence of IL-6 involvement brings insight into the possible mechanisms involved in CCP treatment mitigating SARS-CoV-2 severity.
本研究探讨了细胞因子在 SARS-CoV-2 感染的门诊患者早期输注 COVID-19 恢复期血浆（CCP）时观察到的有益结果中可能发挥的作用。我们发现，早期接受 CCP 治疗的患者的促炎细胞因子 IL-6 显著更快地下降。在感染后期接受 CCP 治疗的 COVID-19 参与者则没有产生相同的效果。早期 CCP 治疗后 IL-6 水平的降低表明炎症在 COVID-19 进展中可能发挥作用。IL-6 参与的证据为 CCP 治疗减轻 SARS-CoV-2 严重程度的可能机制提供了新的见解。
Zotero 插件